In a move designed to expand access to the oral COVID-19 antiviral treatment, the US Food and Drug Administration has authorized pharmacists to prescribe Pfizer Inc.'s Paxlovid (nirmatrelvir/ritonavir) under certain conditions. Paxlovid has emerged as the leading treatment to prevent COVID-19 from worsening in patients at high risk of severe outcomes, but prescribing restrictions and the logistics of getting the treatment to patients within five days after symptoms begin have limited use of the treatment.
Pfizer Sees Expanded Access To Paxlovid With Pharmacist Prescribing
Giving prescribing authority to pharmacists could improve access to the antiviral for patients at high risk for severe COVID-19. Comirnaty financial outlook is also strengthened based on new US contract.
More from COVID-19
More from Scrip
• By
The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
As ADCs continue to be a growth area globally, a new US-based venture with novel platform technology has emerged from stealth mode with $20m in funding.